Physician profile
Bruce Glassman
NPI 1730151119
$10,860.64
in general payments reported to CMS, 2019-2025
46 companies · $2,066 in 2025
The $2,066 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,179 · 2020: $542 · 2021: $969 · 2022: $1,218 · 2023: $1,733 · 2024: $2,154 · 2025: $2,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,764 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,763.76 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,979.69 | 2019-2025 | |
| Leo Pharma INC. | $770.39 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $734.91 | 2020-2025 | |
| Galderma Laboratories, L.P. | $695.08 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $651.76 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $639.09 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $615.27 | 2019-2025 | |
| Amgen INC. | $472.87 | 2019-2024 | Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $345.66 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $345.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $333.12 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $330.68 | 2022-2024 | Vtama |
| Ucb, INC. | $312.29 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $303.20 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Lilly USA, LLC | $223.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Glassman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.